Laboratory and Point-of-Care Testing for COVID-19: A Review of Recent Developments

Ravi Kalia 1, Rishi Kaila 2, Payal Kahar 3, Deepesh Khanna 4

Introduction And Background
COVID-19, a severe respiratory syndrome, caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), led to a pandemic when it originated in Wuhan, China in 2019 and spread across the globe throughout 2020 [1,2]. SARS-CoV-2 is an RNA, positive-sense, single-stranded, enveloped beta coronavirus and shows greater than 96% identity to a known bat coronavirus [3,4]. As of July 2022, there have been 558 million cases and 6.4 million deaths worldwide associated with SARS-CoV-2 as reported by the Centers for Disease Control and Prevention (CDC) [5].

The incubation period for COVID-19 is approximately 2-14 days and frequently individuals present with fever, cough, muscle/body aches, fatigue, and shortness of breath [6]. Infected individuals may either be asymptomatic or symptomatic with mild or severe symptoms. The transmission is dependent upon direct contact, fomites, or exposure to virus droplets, especially if the exposed individual is within 6 feet away from an infected individual [6]. Some major COVID-19 complications include respiratory dysfunction, cardiovascular dysfunction, blood clotting, and ocular manifestations. Individuals can be protected against this virus by way of social distancing, wearing masks, as well as receiving the vaccine [6]. At this moment, there is four FDA emergency use authorization (EUA) approved COVID-19 vaccines on the market - Pfizer-BioNTech, Moderna, Johnson & Johnson, Oxford Astrazeneca, and Novavax - which are effective and significantly reduce the risk of severe illness [3,4,7-10].

When the pandemic was classified by WHO, researchers worldwide rushed to decode the genome and were able to formulate diagnostic protocols utilizing nucleic acid amplification techniques (NAAT). These techniques were limited to certain laboratories and were not able to give rapid results. However, soon after, commercially generated rapid assays were brought to market and individuals were either able to be tested at their local pharmacy or home within minutes. This set a new standard of testing during the pandemic. These new assays that tested for antigens or antibodies varied in their detection modality.

In a pandemic, control is essential to limit the spread of any virus. With the emergence of COVID-19 in Wuhan, contact tracing was not available which ultimately led to the 2020 pandemic. However, with the development of COVID-19 rapid testing, the rate of infections has lessened and has allowed for some return to normalcy. As these COVID-19 tests and mechanisms have not been discussed yet, in this article, we aim to guide individuals to choose the appropriate testing modality based on the overall COVID-19 situation and to highlight certain limitations as well as advantages associated with some of these testing kits [11].

Review
Methods
Authors browsed PubMed articles using the keywords "SARS-CoV-2," "COVID-19 Tests," "COVID-19 Rapid
tests, "COVID-19 Antigen Tests," "COVID-19 Antibody Tests," "COVID-19 Diagnostic," and "COVID-19 RT-PCR." Additionally, the authors searched CDC, WHO, and FDA's website for specific antigens, antibodies, nucleic acid, and point-of-care tests specific to SARS-CoV-2. On Google Scholar, we searched using the same parameters as PubMed and looked at specific clinical studies as well as any review articles that pertained to COVID-19 diagnostic tests. The literature review was restricted to articles published in English. Authors used Google to search for reputable websites to attain background knowledge about the virus. The published papers that were chosen were written in 2020-2021.

Discussion

There are a variety of COVID-19 tests available for use. However, they are separated based on laboratory or point-of-care use. Figure 1 shows COVID-19 diagnostic tests with FDA EUA as of July 2022. All these tests have been given FDA EUA so they can be specifically utilized for the pandemic.

Regarding the laboratory tests, reverse-transcriptase polymerase chain reaction (RT-PCR) is generally used to determine the presence of SARS-CoV-2 infection inside the body of COVID-19 suspected patients. These NAAT assays detect RNA-dependent RNA polymerase, nucleocapsid, spike, and envelope genes as well as those that are present in the initial reading frame [11-13]. However, some tests have used antibodies or antigens to determine if viral nucleocapsid proteins are present. In antibody tests, the antibodies that are measured can either range from a combination of these or singularly - IgA, IgG, IgM, and total immunoglobulin. It has been noted that those tests that detect total immunoglobulin and/or IgG antibodies have shown higher accuracy than other specific antibody tests [11]. For antigen tests, viral SARS-CoV-2 protein is targeted from either nasopharynx, nasal cavity, or saliva, especially the viral nucleocapsid protein due to sheer abundance [11,14]. These antigen-based detection tests utilize chromatographic digital, microfluidic immunofluorescence, as well as lateral flow immunoassays and can be completed at home or in a laboratory [11,15]. Sensitivity and specificity have been included for each of these testing kits as it highlights the kit's ability to detect the COVID-19 infection (sensitivity) and to exclude any other infections in the body (specificity). It has been noted that antigen tests are less sensitive than molecular tests as
molecular tests amplify traces of viruses for detection. The differences in sensitivity can be attributed to false-negative results or missed detections of COVID-19. On the other hand, the specificity for these antigen tests is close to molecular tests, the difference attributed to higher false-positive results or incorrectly detecting a virus that is not present [16]. Table 1 summarizes the laboratory COVID-19 tests.

| Name of Test                             | Type of Test | Mechanism                                      | FDA Approved? | Rapid Test? | Prescription Based? | Sensitivity (+) | Specificity (-) |
|-----------------------------------------|--------------|------------------------------------------------|---------------|-------------|---------------------|----------------|-----------------|
| Simplexa COVID-19 Direct Kit [17]        | Molecular    | Reverse Transcription Polymerase Chain Reaction (RT-PCR) | EUA           | No          | No                  | 100%           | 100%            |
| Cobas SARS-CoV-2 Test & Influenza A/VB [18] | Molecular    | RT-PCR                                         | EUA           | No          | No                  | 100% SARS-CoV-2; 98.4% Influenza A; 97.9% Influenza B | 100% SARS-CoV-2; 98.5% Influenza A; 99.4% Influenza B |
| DxTerity COVID-19 Test [19]              | Molecular    | RT-PCR                                         | EUA           | No          | No                  | 97.3% Symptomatic Patients; 84.6% Asymptomatic Patients | 90.0% Symptomatic Patients; 99.0% Asymptomatic Patients |
| Beckman Coulter’s Access SARS-CoV-2 IgG II [20] | Antibody     | IgG, Paramagnetic particle chemiluminescent assay | EUA           | No          | No                  | 100%           | 99.6%           |
| ACON SARS-CoV-2 IgG/IgM Rapid Test [21]  | Antibody     | IgG & IgM, Lateral Flow assay                   | EUA           | Yes         | Yes                 | 99.1%          | 98.2%           |
| OmniPATH COVID-19 Total Antibody ELISA Test [22] | Antibody     | Total Antibodies (IgG, IgA, IgM) - ELISA       | EUA           | Yes         | No                  | 100% (15 days post-symptoms) | 100% (15 days post-symptoms) |
| Celltrion DiaTrust COVID-19 Antigen Rapid Test [23] | Antigen     | Lateral Flow Immunoaassay                      | EUA           | Yes         | Yes                 | 93.33%         | 99.03%          |
| BD Veritor System [24]                   | Antigen      | Chromatographic Assay                          | EUA           | Yes         | No                  | 89.6%          | 98.8%           |
| Simoa SARS-CoV-2 N Protein Antigen Test [25] | Antigen      | Paramagnetic microbead-based immunoassay        | EUA           | Yes         | No                  | 97.7%          | 100%            |

**TABLE 1: Laboratory COVID-19 tests**

**Nucleic Acid Amplification Tests (NAATs)**

With the emergence of SARS-CoV-2, NAATs have been at the forefront of diagnosing an active and acute infection with the highest amount of sensitivity [26]. In accordance, there have been many developed diagnostic NAAT assays including RT-PCR, Loop-mediated isothermal amplification (LAMP), and CRISP assays [27,28]. These NAAT assays detect RNA-dependent RNA polymerase, nucleocapsid, spike, and envelope genes as well as those that are present in the initial reading frame [11-13]. There are currently 243 molecular-based COVID-19 tests that have been given emergency EUA from the FDA and the majority of these utilize RT-PCR [11].

**Real-Time PCR Tests**

To detect the COVID-19 virus molecularly, an analysis of the nucleic acids in a respiratory sample is completed. RT-PCR is the most commonly used laboratory method currently employed to detect COVID-19. This technique has been used to detect other viruses such as MERS-CoV and SARS-CoV [12,29,30]. Many primers and probes exist that can be used in RT-PCR to confirm the SARS-CoV-2 virus. RT-PCR tests can vary in length of time it takes to complete. Currently, there are two approaches that are used, a one-step and a two-step approach. The one-step approach involves the RT and DNA polymerase reaction being completed in the same reaction tube which is the preferred detection method for SARS-CoV-2 [27]. The two-step approach has the RT and DNA polymerase being detected in separate reaction tubes. One RT-PCR machine can analyze a range of one-to-many hundreds of samples in a given time frame. RT-PCR test results depend on the integrity of primers and probes used, sample collection methods, suited controls, and temperature control reliance. In addition, negative control and positive control are employed. Negative controls check
against sample cross-contamination and positive controls ensure that the reagents, probes, and primers are accurate. The CDC recommends utilizing a human specimen control for better sample lysis and integrity of extraction reagents to markedly reduce false-negative results [11,31].

**Simplexa COVID-19 Direct Kit, Cobas SARS-CoV-2 and DxTerity COVID-19 Test**

The Simplexa COVID-19 direct assay RT-PCR diagnostic panel under EUA targets two genes, the S gene, and ORF1ab. RT-PCR assays typically involve more than one gene target to ensure the accuracy of COVID-19 diagnosis. The Simplexa COVID-19 direct assay is positive when both the ORF1ab and S gene targets are positive. If any of the two assays are negative, the results suggest a sample at a concentration near or below the detection limit of the test or a mutation in one of the gene target regions [17].

The Cobas SARS-CoV-2 and Influenza A/B protocol employ detection probes specific to SARS-CoV-2, sarbecovirus, influenza A, influenza B, and RNA internal control nucleic acid. Coronavirus, influenza A, B, and RNA internal Control detection probes are also labeled with unique fluorescent dyes acting as a reporter [18].

The DxTerity COVID-19 Test Collection kit protocol uses gene targets from the N (nucleocapsid) gene, E (envelope) gene, and ORF1ab region. Additionally, the human RNase P gene serves as a gene target internal and extraction control. The SalivaDirect RNA-extraction free, dualplex RT-PCR test protocol does not require saliva collection tubes with preservatives, or any special equipment for nucleic acid extraction. Saliva is pretreated with proteinase K followed by a heat inactivation step and then added to the test using reliable 2019-nCoV_N1 and RP (ribonuclease) primer and probe sets developed by the US CDC. The human RP probe was modified to use a different fluorophore so the primer/probe set could be used together in a dualplex setup to minimize the number of tests run to 1 [19].

**Antibody-Based Testing**

Antibody-based assays preferentially target SARS-CoV-2's nucleocapsid protein as well as the spike protein, using either ELISA, chemiluminescence immunoassays (CLIA), or lateral flow immunoassays that have been assessed in various systemic studies [11,32-34]. In these tests, the antibodies that are measured can either range from a combination of these or singularly - IgA, IgG, IgM, and total immunoglobulin. It has been noted that those tests that detect total immunoglobulin and/or IgG antibodies have shown higher accuracy than other specific antibody tests [8]. Also, these serological tests should not be conducted during the earlier phases of the infection due to a high possibility of a false negative; it has been optimally recommended to test after three or four weeks of symptoms [11,35,36]. Although they are not commonly used to diagnose active infection, antibody tests are beneficial in epidemiology surveys whereby a specific infection rate can be found for a certain region or demographic [11]. A point of concern that these antibody tests have shown is of cross-reactivity with other human coronaviruses can lead to a high degree of false positivity [37,38]. The CDC is aware of such reactivity and has asked examinees to confirm their diagnosis with a second antibody assay, preferentially a different type [11,35].

There are 78 antibody diagnostic tests for SARS-CoV-2 listed under FDA’s EUA. However, testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The kits are differentiated based on what they are testing for and their methods. While some tests are testing for total antibody count, others are specific for IgG and IgM. The majority of these testing kits use either ELISA, Digital Lateral Flow, photometric immunoassay, lateral flow, or enzyme-linked fluorescent assay (ELFA). FDA has noted that these antibody tests are not validated to evaluate immunity from a SARS-CoV-2 infection or after vaccination. Furthermore, they should only be ordered by healthcare professionals who are knowledgeable about the limitations of such kits [59].

**Beckman Coulter’s Access SARS-CoV-2 IgG II**

Early in the outbreak, Beckman Coulter designed one of the first antibody testing kits to determine an adaptive immune response to SARS-CoV-2 [40]. It is used to qualitatively detect antibodies (IgG) against the virus’s spike proteins in human plasma using a paramagnetic particle, chemiluminescence immunoassay. In a clinical study, it had been highlighted that Beckman Coulter’s testing kit showed a 99.8% negative percent agreement (specificity) and a 100% positive percent agreement (sensitivity) - exemplifying its limited number of false positives and false negatives [40]. Like other antibody testing kits, individuals should test for antibody presence only after several days post-infection. For an active infection, a molecular diagnostic test should be utilized such as an RT-PCR test rather than an antibody test to further minimize any false negatives or positives. Additionally, a negative result can occur if not enough antibodies are present in the specimen. Beckman Coulter specifies that a negative or positive result should be confirmed with an antibody test from another manufacturer for the highest accuracy. Also, clinical performance has not been determined for all COVID-19 viral variants currently in circulation but is reflective of the variants found at the time of development including Alpha, Beta, Gamma, and Delta. It has been noted that interferences and erroneous results can arise due to an individual utilizing immunoglobulin-based treatments, those that are exposed to animals, and to those that produce excess rheumatoid factor or alkaline phosphatase [40].
Conducted. It is noted that positive results from this test do not eliminate any bacterial or viral co-infections.

For these particular tests, viral SARS-CoV-2 protein is targeted from either nasopharynx, nasal cavity, or saliva, especially the viral nucleocapsid protein due to sheer abundance [11,14]. These antigen-based detection tests utilize chromatographic digital, microfluidic immunofluorescence, as well as lateral flow immunoassays and can be completed at home or in a laboratory [11,15]. The point-of-care tests (POCTs) and rapid diagnostics tests (RDTs) rely mostly on antigen or antibody detection and can be completed within minutes without laboratory involvement [11]. Currently, there are only a few POCTs that have been given EUA by the FDA. Although these POCTs and RDTs have an average specificity near 100%, they are less sensitive than NAATs with the average sensitivity being close to 55% with a maximum of 97% [11,22,40,41]. However, these simple-to-use POCTs are beneficial when there is a high viral load, especially during the earlier period of the illness [42,43]. It has been highlighted that WHO does not recommend POCTs for acute patient care testing if there are NAATs available, especially due to the lower sensitivity percentage seen with POCTs [14]. These POCTs have the ability to lead a patient away from their emergent diagnosis [11].

At this moment, under FDA’s EUA, there are 23 antigen diagnostic tests for SARS-CoV-2 [44]. Although the FDA has not approved these testing kits, they are released to the public and health officials in an attempt to alleviate the pandemic spread of SARS-CoV-2 [44]. For each of these tests, FDA has given specific limitations and conditions of authorization, especially in regard to certain approved testing laboratories. Some of them are prescription-ordered tests, while others are over the counter (OTC) or direct-to-consumer (DTC) home collection tests that are sent to laboratories for processing after sample collection [43]. Some of the lateral flow immunoassay antigen-based tests are Celltrion DiaTrust COVID-19 Ag Rapid Test, CareStart COVID-19 Antigen Test, Sofia SARS Antigen FIA, QuickVue SARS Antigen Test, Clip COVID Rapid Antigen Test. Furthermore, there are testing kits that rapidly detect SARS-CoV-2 and Flu A/B - BD Veritor System for Rapid Detection, Status COVID-19/Flu, Sofia 2 Flu + SARS Antigen FIA [44]. Some of these are described below.

**Celltrion DiaTrust COVID-19 Antigen Rapid Test - Lateral Flow Immunoassay**

Celltrion DiaTrust's COVID-19 Rapid Test is a lateral flow immunoassay, a prescription-based test used to detect SARS-CoV-2's nucleocapsid and receptor-binding domains on the spike proteins. Individuals should swab their nasopharyngeal within seven days of symptom onset to retrieve a result. Positive results indicate the presence of antigens, however at times, with all POCTs, a second, different confirmatory test should be conducted. It is noted that positive results from this test do not eliminate any bacterial or viral co-infections.
and negative results should be treated as presumptive and confirmed with a molecular assay. As with the other rapid tests, Celltrion cannot differentiate between the SARS-CoV and SARS-CoV-2 strains. All results should be considered in context with the patient’s history as well as other results [45].

**BD Veritor System - Chromatographic Assay/SARS-CoV-2, Flu A+B**

BD’s Veritor System is used for the rapid detection of Flu A and B as well as SARS-CoV-2. It uses a chromatographic immunoassay to detect the nucleocapsid antigen of SARS-CoV-2, Influenza A or B [23]. Like the Sofia 2 Flu + SARS testing kit, it is able to detect both flu antigens as well as SARS antigens. It is a point-of-care test, however only intended under healthcare professional guidance [24]. All negative results received from this test should be treated as presumptive and should not be taken at face value without confirmation with a molecular-based assay or taking into account clinical signs and exposures [24]. For this test, the swab is inserted into a nostril and swirled in an extraction reagent tube. Following, some drops are added to the sample well and the test is run for 15 minutes. Then, the sample well is inserted into the BD Veritor Plus Analyzer for analysis and the results will appear on the display window [24]. Furthermore, Young et. al has stated that Veritor test allows for a more rapid SARS-CoV-2 testing by way of nasal swabbing. However, it has shown a less than 100% positive percent agreement when compared to PCR [46]. However, they also concluded that Sofia 2 Flu + SARS and Veritor have a high degree of agreement for SARS-CoV-2 detection [46]. Their results suggest that as the number of SARS-CoV-2-associated symptoms increases, the higher the sensitivity of the antigen-based test, allowing for a higher probability of an accurate result [46].

**Simoa SARS-CoV-2 N Protein Antigen Test - Paramagnetic Microbead-Based Immunoassay**

Quanterix Corp’s Simoa antigen test detects the presence of nucleocapsid protein from nasopharyngeal samples taken by an individual’s healthcare provider within 14 days of symptom onset. Quanterix is in the process of converting this test kit to a home-based sample collection kit for further rapid diagnosis. Simoa’s Antigen Test utilizes a microbead-based sandwich ELISA coupled with Simoa (single molecule array) technology. However, positive results cannot differentiate between SARS-CoV-2 and SARS-CoV or any co-infections. In a clinical study of 126 nasopharyngeal swab specimens from suspected SARS-CoV-2-infected individuals, RT-PCR and Simoa Protein Antigen Test were compared. It was found that Simoa has a 97.7% positive agreement and a 100% negative agreement with PCR. However, as the symptom onset days progressed, Simoa had a less than 100% positive agreement with PCR, specifically noting a 94.7% agreement when onset progressed to 8-14 days. In a separate study, Shan et al. highlight that Simoa SARS-CoV-2 can successfully and effectively detect SARS-CoV-2 antigen levels in both saliva and blood, leading to the future potential of a point of care, at-home sample kit. It has been noted, from their study, that Simoa immunoassay shows greater than 98% negative agreement and greater than 90% positive agreement with PCR molecular testing in regards to symptomatic, asymptomatic, and pre-symptomatic individuals during the first week of infection [25,47].

**Point-of-Care Testing**

At this moment, there are five at-home COVID-19 tests that have been given EUA from the FDA, with four that will be sold OTC without a prescription. Three of these are antigen-based tests, while the other two are molecular-based via isothermal amplification. These tests are revolutionizing the healthcare field as consumers now do not have to extended periods to retrieve their results. These new tests are more convenient, less expensive, and are essential for communities, workplaces, and schools to rapidly screen individuals. However, they have not gone through FDA's extensive approval process and can be revoked if the FDA determines any ineffectiveness. These POCTs are significant in decentralized health care environments where PCR-based tests are inaccessible or with longer turnaround times [11,48]. Table 2 summarizes the point-of-care COVID-19 tests.
### TABLE 2: Point-of-care COVID-19 tests

Although these POCTs show an accuracy rate of 80%, it has been highlighted that the antigen POCTs miss many asymptomatic infections, whereas the molecular-based POCTs are more effective in diagnosing an infected asymptomatic individual. However, the gold standard SARS-CoV-2 test is a PCR-based laboratory test that is more sensitive, and specific and can detect the virus at lower levels. A CDC study showed that Abbott’s antigen-based test found only 54% of infections in asymptomatic individuals [54]. Moreover, a compiled review of 68 studies has found that rapid antigen-based tests identify nearly 58% of asymptomatic individuals and 72% of symptomatic individuals, so it is imperative that those using a POCT should continue wearing their masks, practice social distancing as well as other precautions. In fact, those with a negative result should identify any symptoms that may be associated with SARS-CoV-2 and look to re-test within 24-48 hours. It is imperative for individuals to double check their results with a laboratory-based PCR test as those are more accurate than POCTs [54].

**Ellume COVID-19 Home Test - Antigen Based**

The first at-home tests released can be purchased without a prescription. It is an antigen-based viral protein diagnostic test with results delivered to a smartphone application within 20 minutes. From a late-2020 clinical trial, it has been noted that Ellume can detect 96% of positive cases and 100% of negative cases from asymptomatic individuals, however only 91% of positive cases and 96% of negative cases from asymptomatic individuals (FDA). It is likely infected individuals may receive a negative result due to the high rate of false negatives that this antigen-based test can produce, especially those who are pre-symptomatic or post-symptomatic. Symptomatic individuals have a greater statistical chance to receive an accurate diagnosis than those not showing any symptoms. It has been highlighted that asymptomatic individuals with negative results should receive additional testing to confirm the proper diagnosis. This inexpensive test will be widely available soon with a price point of $30. However, it cannot be used for children under the age of two. To obtain a test result, the nasal swab is inserted in each nostril until the swab cap or child adapter touches the nose with one’s smartphone three inches away and opened on the Ellume COVID-19 Home Test app. Once the results are received on the app, they can be shared with any healthcare professional [51,55].

**Abbott’s BinaxNOW COVID-19 Ag Card Home Test - Antigen-Based**

Abbott’s BinaxNOW COVID-19 Test is a home-use, lateral flow immunonassay used for the detection of COVID-19’s nucleocapsid protein antigen and conducted with assistance from a digital health solution, eMed. This home test uses an immunochromatographic membrane with specific SARS-CoV-2 antibodies and a control antibody to establish a test strip. To generally perform, a nasal swab is collected by the individual from both nostrils, six drops of reagent are added to the top well and after a few swab rotations, the test strip is brought into contact with the swab. After the card is sealed, a QR code is scanned and the results are shown on the card. The test results are visually shown within 15 minutes with pink/purple-colored positive resultant lines. This test can be shipped to a home address and with the guidance of a trained telehealth professional via a video call, the BinaxNOW test can be self-administered with results appearing on their NAVICA app. The test is prescribed by an individual’s healthcare provider within the first week of symptom onset and can only be performed under a telehealth provider’s supervision. This test is designed for individuals four years and older with parental assistance needed for younger children. The nucleocapsid protein antigen is detectable when the anterior nasal (nares) is swabbed. However, a negative result should be evaluated with an individual’s symptoms, exposures, and travel history [56,57]. Additionally, the test is sold in packs of two, so an individual can confirm their diagnosis by re-testing. It has been noted that these kits will be available in grocery and drug stores for purchase as OTC kits [54].

| Name of Test | Type of Test | Mechanism | FDA Approved? | Rapid Test? | Prescription Based? | Sensitivity (+) | Specificity (-) |
|--------------|--------------|-----------|--------------|------------|---------------------|----------------|----------------|
| Ellume COVID-19 Home Test [49] | Antigen | Lateral Flow | EUA | Yes | No | 95% | 97% |
| Abbott BinaxNOW COVID-19 Ag Card Home Test [50] | Antigen | Lateral Flow | EUA | Yes | No | 91.7% | 100% |
| QuickVue At-Home OTC COVID-19 Test [51] | Antigen | Lateral Flow | EUA | Yes | No | 83.5% | 99.2% |
| Cue COVID-19 Test for Home and Over the Counter (OTC) Use [52] | Molecular | Isothermal Nucleic Acid Amplification | EUA | Yes | No | 91.5% | 95.7% |
| Lucira COVID-19 All-In-One Test Kit [53] | Molecular | Loop Mediated Isothermal Amplification | EUA | Yes | Yes | 94% | 98% |
Sensitive testing kits, the rate of COVID-19 cases would not have decreased as much as it has. The near-to-threshold post-infection, posing a problem for antibody-based tests in the future.

There are some published articles that highlight that COVID-19 antibodies may decrease to lower than the negative control chambers as well as chambers that specifically react with the RNA of SARS-CoV-2. Within each chamber, the eluant is able to enter a fluidic molecule and begin the RT-LAMP reaction whereby a heating element is activated to gauge the reaction chamber. In this Test Unit, there are positive control chambers as well as chambers that specifically react with the RNA of SARS-CoV-2. Within 30 minutes, an amplification-RNA-positive color change is detected by a microprocessor, and by way of a diagnostic algorithm, a LED indicator is lit. The LED results can either represent invalid, positive, or negative.

Before releasing this test, Lucira Health determined that when testing cross-reactivity with 33 commensal organisms, none of the organisms were cross-reactive with Lucira’s test. Furthermore, they were able to test the reproducibility of the test by challenging untrained, intended users to utilize their test kit in order to determine if users are able to follow their directions and obtain expected results.

Although the information is available for various tests, there is not enough comparative clinical information to conclude that a certain testing kit is far superior to the others. It is noted that NAATs are more sensitive and specific for acute infections, they are the gold standard when it comes to determining if an individual is infected with SARS-CoV-2. In the future, once more clinical, prospective and retrospective studies are completed we will be able to fully compare the efficacy and accuracy of each of these testing kits. Also, there are some published articles that highlight that COVID-19 antibodies may decrease to lower than the threshold post-infection, posing a problem for antibody-based tests in the future.

Conclusions

Appropriate testing is of utmost importance in alleviating and downgrading a pandemic. Without specific or sensitive testing kits, the rate of COVID-19 cases would not have decreased as much as it has. The near-to-

Limitations

Although the information is available for various tests, there is not enough comparative clinical information to conclude that a certain testing kit is far superior to the others. It is noted that NAATs are more sensitive and specific for acute infections, they are the gold standard when it comes to determining if an individual is infected with COVID-19. In the future, once more clinical, prospective and retrospective studies are completed we will be able to fully compare the efficacy and accuracy of each of these testing kits. Also, there are some published articles that highlight that COVID-19 antibodies may decrease to lower than the threshold post-infection, posing a problem for antibody-based tests in the future.
definite method to determine SARS-CoV-2 infection is by way of NAA Ts, specifically those using RT-PCR. It has been highlighted that antigen and antibody testing are rapid to determine infection. However, they should not be used in acute infections and should be confirmed with a NAAT. False positives, negatives, and cross-reactivity can occur with these testing kits, so it is imperative for an individual to be informed about all of these testing kits. With newer tests, we should see a shift towards more at-home, rapid assays that have high specificities as well as sensitivities.

**Additional Information**

**Disclosures**

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Mohamadian M, Chiti H, Shoghi B, Biglari S, Parsamanesh N, Esmailzadeh A: COVID-19: virology, biology and novel laboratory diagnosis. J Gene Med. 2021, 23:e3503. 10.1002/jgm.3303
2. Hapsley V, Aziz D, Kahrar P, Khanna D, Johnson KE, Parmar MS: COVID-19 and pregnancy: risk, symptoms, diagnosis, and treatment. SN Compr Clin Med. 2021, 5:1477-83. 10.1007/s42359-021-00915-2
3. Zheng I: SARS-CoV-2: An emerging coronavirus that causes a global threat. Int J Biol Sci. 2020, 16:1678-85. 10.7150/ijb.45053
4. Loffi M, Hablin MR, Rezaei N: COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020, 508:254-66. 10.1016/j.cca.2020.05.044
5. WHO Coronavirus (COVID-19) Dashboard. (2021). Accessed: August 17, 2022: https://covid19.who.int.
6. Backer S, Rezene A, Kahrar P, Khanna D: Socioeconomic determinants of COVID-19 incidence and mortality in Florida. Cureus. 2022, 14:e22491. 10.7759/cureus.22491
7. Azevedo RB, Botelho BG, Hollanda JV, et al.: Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021, 35:4-11. 10.1038/s41371-020-0587-4
8. Douglas KA, Douglas VP, Moschos MM: Occular manifestations of COVID-19 (SARS-CoV-2): a critical review of current literature. In Vivo. 2020, 34:1619-28. 10.21873/inivo.11952
9. Patel R, Kaki M, Potluri VS, Kahrar P, Khanna D: A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum Vaccin Immunother. 2022, 18:200285. 10.1080/21645515.2021.2002085
10. Coronavirus (COVID-19) update: FDA authorizes emergency use of Novavax COVID-19 vaccine, adjusted . (2022). Accessed: July 25, 2022: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-...
11. Lai CK, Lam W: Laboratory testing for the diagnosis of COVID-19. Biochem Biophys Res Commun. 2021, 538:226-30. 10.1016/j.bbrc.2020.10.069
12. Corman VM, Landt O, Kaiser M, et al.: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveill. 2020, 25:200045. 10.2807/1560-7917.ES.2020.25.2.200045
13. Chu DK, Pan Y, Cheng SM, et al.: Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem. 2020, 66:549-55. 10.1093/clinchem/hvaa029
14. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim Guideline . (2021). Accessed: October 6, 2021: https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2-infection-using-rapid-immunooa....
15. Emergency Use Authorizations. (2015). Accessed: February 6, 2015: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-authorizations.
16. Overview of testing for SARS-CoV-2 (COVID-19). (2022). Accessed: August 25, 2022: https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html.
17. Simplexra® COVID-19 direct kit. (2020). Accessed: May 20, 2020: https://molecular.diasorin.com/us/kit/simplexra-covid-19-direct-kit/.
18. cobas® SARS-CoV-2. (2021). Accessed: June 3: https://diagnostics.roche.com/uk/en/products/params/cobas-sars-cov-2-influenza-a-b-nucleic-acid-test.html.
19. SARS-CoV-2 Coronavirus Test. (2022). Accessed: August 8, 2022: https://dxterity.com/sars-cov-2-test-covid-19/?utmTracking=e6a912a9-c5fb-49f1-94ab-cbeb54115ae4%3C7aada316-fa6a-407.7....
20. Access SARS-CoV-2 IgG antibody test. (2020). Accessed: March 50, 2020: https://www.beckmancoulter.com/products/immunoassay/access-sars-cov-2-igg-antibody-test.
21. ACON SARS-CoV-2 IgG/IgM rapid test. (2022). Accessed: August 17, 2022: https://www.aconlabs.com/covid-19/.
22. COVID-19 total antibody ELISA test. (2020). Accessed: October 14, 2020: https://www.thermofisher.com/covid-19-antibody-testing/us/en/solutions/OmniPATH-COVID19-Total-Antibody-ELISA-Test.html.
23. DiaTrust™ COVID-19 Ag Rapid Test - Celltrion. (2022). Accessed: May 22, 2022: https://www.celltrion.com/en-us/kit/DiatrustAg.
24. Hassan F, Nguyen A, Formanek A, Ibell J, Selvarangan R: Comparison of the BD Veritor System for Flu A+B with the Alere BinaxNOW influenza A&B card for detection of influenza A and B viruses in respiratory specimens from pediatric patients. J Clin Microbiol. 2014, 52:906-10. 10.1128/JCM.02484-13
25. Quantexis receives FDA emergency use authorization for SARS-CoV-2 N protein antigen test. (2021). Accessed: January 11, 2021: https://www.quantexis.com/press-releases/quantexis-receives-fda-emergency-use-authorization-for-sars-cov-2-n-protein-

26. Patel A, Jernigan DB: Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020, 69:140-6. 10.15585/mmwr.mm6905e1

27. Carter LI, Garner LV, Smoot JW, et al.: Assay Techniques and Test Development for COVID-19 Diagnosis. ACS Cent Sci. 2020, 6;591-605. 10.1021/acscentsci.0c00501

28. Yan C, Cui J, Huang L, et al.: Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay. Clin Microbiol Infect. 2020, 26;773-9. 10.1016/j.cmi.2020.04.001

29. Drosten C, Seilmaier M, Corman VM, et al.: Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis. 2015, 15:745-51. 10.1016/S1473-5897(15)00154-3

30. Mackay IM, Arden KE, Nitsche A: Real-time PCR in virology. Nucleic Acids Res. 2002, 30;1292-305. 10.1093/nar/30.6.1292

31. CDC 2019-nCoV Real-Time RTPCR Diagnostic Panel (CDC) - Manufacturer Instructions/Package Insert. (2019). https://www.cdc.gov/coronavirus/2019-ncov/lab/laboratory-tests.html.

32. Deeks JJ, Dinnes J, Takwoingi Y, et al.: Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020, 6;CD013562. 10.1002/14651858.CD013562

33. Liscoa Bastos M, Tavaiziva G, Abidi SK, et al.: Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020, 570;cm2516. 10.1136/bmj.m2516

34. Cai N, Belletha F, Corsor F, et al.: Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 22 April 2020 and public health implications. Euro Surveill. 2020, 25:2020098.

35. CDC: Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings. (2022). Accessed: January 24, 2022: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.

36. Cheng MP, Yansouni CP, Basta NE, et al.: Serodiagnosis for severe acute respiratory syndrome-related coronavirus 2: a narrative review. Ann Intern Med. 2020, 173;450-60. 10.7326/M20-2854

37. Lustig Y, Keler S, Kolodyr R, et al.: Potential antigenic cross-reactivity between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and dengue viruses. Clin Infect Dis. 2021, 73:e2444-9. 10.1093/cid/ciaa1207

38. Che XY, Qiu LW, Liao ZY, et al.: Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43. J Infect Dis. 2005, 191;2033-7. 10.1086/430355

39. In vitro diagnostics EUAs - serology and other adaptive immune response tests for SARS-CoV-2. (2022). Accessed: July 25, 2022: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices.

40. ACON SARS-CoV-2 IgG/IgM rapid test. ACON, San Diego, CA; 2019.

41. Sinay A, Tesfaye A, Desale A, et al.: Diagnostic performance of SARS-CoV-2 IgM/IgG rapid test kits for the detection of the novel coronavirus in Ethiopia. J Multidiscip Healthc. 2021, 14:171-80. 10.2147/JMDH.S90711

42. Arons MM, Hatfield KM, Reddy SC, et al.: Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020, 382;2081-90. 10.1056/NEJMoa2008457

43. Weiss A, Jellings M, Sommer MO: Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: a systematic review and meta-analysis. ElifeMedicine. 2020, 58;102916. 10.1016/j.elifeco.2020.102916

44. In vitro diagnostics EUAs - antigen diagnostic tests for SARS-CoV-2. (2022). Accessed: July 8, 2022: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices.

45. Calltrion DiaTrust COVID-19 Ag rapid test. (2022). Accessed: May 16, 2022: https://www.fda.gov/media/147694/download.

46. Young S, Taylor SN, Cammarata CL, et al.: Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-of-care test. J Clin Microbiol. 2020, 59;10.1128/JCM.03238-20

47. Shan D, Johnson JM, Fernandes SC, et al.: N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection. Nat Commun. 2021, 12;1951. 10.1038/s41467-021-22072-9

48. New at-home COVID-19 tests promise results in minutes . (2021). Accessed: January 4, 2021: https://www.aarp.org/health/conditions-treatments/info-2021/at-home-covid-tests.html.

49. Ellume. Ellume Home Test. Available from: https://www.ellumecovidtest.com/home-test#accuracy.

50. BinaxNOW™ COVID-19 Ag Card home test . (2018). Accessed: May 1, 2018: https://www.globalpointofcare.abbottn/en/product-details/binaxnow-covid-19-home-test-us.html

51. At-Home OTC COVID-19 Test. (2021). Accessed: July 1, 2021: https://quickviewathome.com/wp-content/uploads/2021/07/FQ20359800EN00.docx/jul19202111511.pdf.

52. The Cue™ COVID-19 Test for Home and Over The Counter (OTC) Use. (2022). Accessed: February 1, 2022: https://www.cuehealth.com/products/how-cue-detects-covid-19/

53. Lucira’s Covid-19 All-In-One Test Kit FAQs. (2022). Accessed: July 25, 2022: https://www.fda.gov/media/143809/download.

54. BinaxNOW COVID-19 Ag card home test kit . (2022). Accessed: August 17, 2022: https://binaxna.com/products/binaxnow-covid-19-antigen-self-test?gclid=CjwKCAjw_36HfB伯AELwAphYKIXAv4vAf9lVqE05Js1YcVr3...
55. QuickVue SARS antigen test. (2021). Accessed: July 25, 2022: https://www.pharmacytoday.org/article/S1042-0991(21)00160-2/fulltext.

56. Quidel’s QuickVue® At-Home OTC COVID-19 test receives emergency use authorization for screening use with serial testing. (2021). Accessed: April 1, 2021: https://finance.yahoo.com/news/quidel-quickvue-home-otc-covid-030000032.html.

57. FDA authorizes cue Health’s COVID-19 test for at-home and over the counter use. (2021). Accessed: March 5, 2021: https://www.cuehealth.com/about/press/fda-authorizes-cue-health’s-covid-19-test-for-at-home-and-over-the/.

58. At-Home OTC COVID-19 Test. (2022). Accessed: July 12, 2022: https://quickvueathome.com/wp-content/uploads/2021/07/FQ2039800EN00.docxJul192021115011.pdf.

59. AARP. New at-home COVID-19 tests promise results in minutes. (2022). Accessed: April 1, 2022: https://www.aarp.org/health/conditions-treatments/info-2021/at-home-covid-tests.html.

60. Cue COVID-19 test for home and over the counter (OTC) use. (2021). Accessed: April 1, 2021: https://www.cuehealth.com/products/how-cue-detects-covid-19/.

61. FDA. Lucira’s Covid-19 All-In-One Test Kit FAQs. (2022). Accessed: March 23, 2022: https://www.fda.gov/media/143509/download..